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Tumor Promotion in Rat Liver
by Sydna L. Herren* and Michael A. Pereira*
An initiation/promotion bioassay for chemical carcinogens and tumor promoters has been devel-
oped in rat liver using presumed preneoplastic lesions, foci of y-glutamyltranspeptidase (GGTase-
positive hepatocytes, as the endpoint. To evaluate the tumor-promoting activity of phenobarbital,
rats were administered diethylnitrosamine (DENA), 2.0 mmole/kg, followed by 500 ppm phenobarbi-
tal in their drinking water. After 6 weeks of phenobarbital promotion, the rats had an increased in-
cidence of foci as compared to nonphenobarbital-treated rats. By 50 weeks, the number of foci in the
nonpromoted animals equaled the number observed with promotion. The stability and progression
of GGTase-positive foci was determined in rats that received a 2/3 partial hepatectomy, followed 24
hours later by DENA administration (0.3 mmole/kg). The rats then received 500 ppm phenobarbital
in the drinking water for 7 weeks. After 7 weeks, half of the rats were continued on phenobarbital
and the other half were removed from phenobarbital treatment. The number of foci observed in rats
continued on phenobarbital treatment leveled off after 10 weeks of promotion, while in rats taken
off phenobarbital it did not regress but increased at a slower rate, and, by 56 weeks, approached the
number observed in rats subjected to continuous promotion. At 56 weeks, the size of foci was larger
after continuous promotion. At 81 weeks, all 6 (100%) of the rats on continuous promotion had liver
tumors, while only 3 of 6 (50%) of the rats removed from promotion had tumors. Promotion by
phenobarbital stimulated the growth and decreased the time required for the appearance of
GGTase-positive foci and liver tumors.
Introduction
Initiation/promotion was initially demonstrated in
mouse skin as an increased yield of tumors re-
sulting from repeated applications of croton oil to
mice initiated with a single low does of benzo(a)py-
rene (1-3). These studies resulted in the multistage
theory of carcinogenesis, which has been now ex-
tended to other tissues, including the liver (4, 5).
The first stage, initiation, includes the binding of
the carcinogen to cellular DNA followed by fixation
of the alteration during DNA replication. The al-
tered genotype in the liver is expressed as cells
with altered phenotypes. Cellular replication results
in foci of hepatocytes possessing these altered activ-
ities.
Since the foci of altered hepatocytes are pre-
sumed to be early indicators of initiation in hepato-
carcinogenesis (6, 7), they have been used as the end
point in short-term assays for the detection of chem-
ical carcinogens (8-10). These foci are readily identi-
fiable histochemically as areas possessing either a
decrease in glucose--phosphatase or adenosine tri-
phosphatase or iron accumulation, or an increase in
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y-glutamyltranspeptidase (GGTase) (12-18). In the
present study, a focal increase of GGTase activity
was used as the endpoint because: (a) approximately
90% of the foci stain positive for the enzyme (19), (b)
GGTase is detectable histochemically in adult liver
only in bile duct cells and in rats older than those
used in this study (20) and (c) the enzyme is present
in hyperplastic nodules and hepatocellular carcino-
mas (21). In this communication we describe the re-
lationship of promotion to the incidence and stabil-
ity of GGTase-positive foci.
Materials
Male Sprague-Dawley rats (Charles River Com-
pany, Portage, MI), weighing 175-200 g were used
in these studies. The animals were maintained in ac-
cordance with accepted standards (22). They were
fed Laboratory Chow (Ralston Purina Co., St. Louis,
MO), and given drinking water ad libitum.
Diethylnitrosamine (DENA), reagent grade, was
purchased from Eastman Organic Chemical Co. (Ro-
chester, NY); sodium phenobarbital from Mallin-
crodt, Inc. (St. Louis, MO) or J. T. Baker (Glen Ellyn,
IL); OCT compound and hematoxylin from Fisher
Scientific Company (Pittsburgh, PA); and N-y-L -glu-
tamyl-4-methoxy-2-naphthylamine from Polysciences
(Warrington, PA) and Bachem (Torrence, CA).HERRENAND PEREIRA
Methods
Measurement of GGTase-Positive Foci
At sacrifice, the right lateral liver lobe was re-
moved, cut into 10 x 10 x 2 mm blocks and frozen
in OCT compound as previously described (10). The
blocks were stored at - 800C until they were
sectioned into 8 ,m sections. These sections were
stained for GGTase according to the procedure of
Rutenburg et al. (23) and counterstained with
hematoxylin. The sections were scanned, and foci
with nine or more nuclei scored. Figure 1 depicts a
typical GGTase-positve focus.
Experimental
Effect of Phenobarbital Promotion on the
Number of GGTase-Positive Foci
Groups consisting of 10 male Sprague-Dawley
rats each were dosed with 2.0 mmole/kg DENA by
gavage, followed, 1 week after, by administration of
500 ppm of sodium phenobarbital in the drinking
water. Two weeks after the DENA was adminis-
tered, the rats were subjected to a 2/3 partial hepa-
tectomy or a sham operation. Twenty-four hours
after surgery, the rats were given 100 ppm pheno-
barbital in their drinking water. This reduction in
the concentration of the phenobarbital was due to
its increased toxicity in rats that received the par-
tial hepatectomy. The concentration of phenobarbi-
tal was increased to 250 ppm at 4 weeks after
partial hepatectomy.
Stability and Regression of GGTase-Positive
Foci
Male Sprague-Dawley rats were given a partial
hepatectomy followed 24 hr later by an intragastric
administration of DENA (0.3 mmole/kg) in distilled
water. One week later, all the rats were placed on
500 ppm sodium phenobarbital in their drinking
water. Seven weeks later (8 weeks total), 20 rats
were sacrificed, and only half of the remaining rats
were continued on phenobarbital promotion. Ten
rats from each group were sacrificed at 9, 11, 20 and
56 weeks, and six rats from each group at 81 weeks
after DENA administration. Control rats, treated
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FIGURE 1. GGTase-positive foci. The liver section was stained for GGTase activity and counter-stained with hematoxylin. x 100.
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with phenobarbital but not with DENA, were
sacrificed at 8, 11, 20, 56 and 81 weeks.
Results
Effect ofPhenobarbital Promotion on the
Appearance of GGTase-Positive Foci
The results of the study comparing the effects of
phenobarbital and of partial hepatectomy, on the
incidence of DENA-initiated foci at 6 and 50 weeks,
are shown in Table 1. After 6 weeks of promotion
with phenobarbital and partial hepatectomy, the
rats had an increased incidence of foci as compared
to nonpromoted rats (Group 1 and 2). However, by
50 weeks the number of foci in the nonpromoted
animals equalled the number observed with pro-
motion. This indicated that the initiator determined
the ultimate number of foci, while the promoter de-
creased the latent period required for development
of the foci.
Stability and Progression of GGTase-
positive Foci
The effects of continued versus discontinued pro-
motion by phenobarbital on the incidence of
GGTase-positive foci is shown in Figure 2. At 8
weeks, rats that received DENA administration fol-
lowed by phenobarbital treatment had an increased
incidence of GGTase-positive foci compared to rats
Table 1. Effect of phenobarbital on the incidence of GGTase-positive foci.a
GGTase foci/cm2 of liver sectionb
Partial
DENA Pheno- hepatec-
GP (2 mmoles/kg) barbital tomy 6 wks post DENA 50 wks postDENA
1 + + + 19.8 ± 2.4 (5) 19.4 ± 1.45 (12)
2 + - - 8.3 ± 3.9 (5) 23.2 ± 6.72 (8)
3 - + + 0.8 ± 0.4 (4) 2.33 ± 0.44 (9)
4 - - - 0.2 ± 0.2 (4) 1.28 ± 0.62 (9)
aData from Ford and Pereira (10).
bMeans + standard error ofthe mean for number ofanimals in parenthesis.
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FIGURE 2. Stability ofGGTase-positive foci with continuous vs. discontinuous promotion.
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that received only phenobarbital. The number of
foci observed in rats on continuous phenobarbital
treatment leveled off after 10 weeks of treatment
(week 11 of the experiment). In rats removed from
phenobarbital at 8 weeks, the incidence of foci
initially leveled off and then slowly increased so
that, by 56 weeks, the incidence approached the
level found in rats continued on phenobarbital.
At 56 weeks, the size of the foci in rats continued
on phenobarbital was larger than that in the rats re-
moved from phenobarbital (Fig. 3). The median size
of the foci in rats continued on phenobarbital was
0.1-0.3 mm2, while in rats whose treatment was ter-
minated the median size was 0.03-0.1 mm2 (this dif-
ference was statistically significant atp < 0.001). Foci
larger than 1 mm2 were found only in rats continued
on treatment and represented 3% of the number of
foci. Therefore, phenobarbital did not affect the ulti-
mate incidence of DENA initiated foci, but stimu-
lated the growth of the foci so that they could be
observed earlier.
After 81 weeks, all six rats (100%) continued on
phenobarbital had grossly visible liver tumors,
while only three of the six rats (50%) which were
removed from phenobarbital had tumors (Table 2).
The rats continued on promotion had a total of 30
grossly visible tumors largerthanthe3mmdiameter
and the rats removed from promotion had 17 tu-
mors. In rats not initiated with DENA, only one of
nine rats which had received phenobarbital con-
60r,
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FIGURE 3. GGTase-positive foci size distribution at 56 weeks after DENA administration in rats either continued on or removed
from phenobarbital.
Table 2. Effect ofphenobarbital on the incidence ofDENA-initiated tumors.
Rats with tumors Grossly visible
Group Initiator Promotion per number ofrats tumors (>3 mm)
1 DENA Continued 6 / 6 30
2 DENA Discontinued 3 / 6 17
3 Water Continued 1 / 9 3
4 Water Discontinued 0 / 5 0
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tinuously had tumors, and none of the five rats
which had received phenobarbital for only the initial
7 weeks had tumors.
Discussion
Phenobarbital, when administered to carcinogen
initiated rats, has been shown to promote the in-
duction of liver tumors (24-26) and to enhance the
development of GGTase-positive foci (10, 14, 16,
26-30). The mechanism of phenobarbital enhan-
cement of GGTase-positive foci was investigated in
order to test its relationship to tumor promotion.
Foci of GGTase-positive hepatocytes have been
postulated to be the earliest observable evidence of
initiation in the liver and their number to be a
measure of the extent of the initiation of liver
target cells (11, 31, 32). In the present studies
phenobarbital decreased the time required for the
appearance of DENA-initiated GGTase-positive foci
by increasing their growth rate. However, the
ultimate number of DENA initiated foci was in-
dependent of subsequent phenobarbital treatment.
Kitagawa and Sugano (26) have also demonstrated
that the appearance of foci occurred earlier in
phenobarbital treated rats and that the incidence of
foci was determined by the initiator. Our ob
servations confirm that phenobarbital treatment,
subsequent to DENA initiation, does not appear to
alter the extent ofinitiation but acts to decrease the
time required for the development of GGTase-
positive foci and of tumors.
Tumors contain transformed cells that possess ir-
reversible alterations in their phenotype. In the
present studies, GGTase-positive foci were demon-
strated to be a stable and irreversible lesion.
Cessation of phenobarbital treatment during the
time when foci were appearing did not result in
regression of the foci. Actually, their incidence in
rats whose treatment was discontinued did in-
crease, though at a much slower rate, so that
ultimately it did approach the incidence observed in
rats previously treated with an initiator such as
phenobarbital of the growth rate of established
GGTase-positive foci was demonstrated by the
larger size of the foci at 56 weeks in rats continued
on phenobarbital compared to rats removed from
phenobarbital. Therefore, phenobarbital continued
to stimulate the growth of GGTase-positive foci
after their appearance. When tumors began to
appear at 81 weeks, the incidence was higher in rats
continued on phenobarbital compared to those
removed from phenobarbital. The precursor nature
of GGTase-positive foci to hepatocellular carcinoma
is supported by the fact that the foci are both stable
and irreversible lesions, and that their growth is
enhanced by phenobarbital.
The ability of a substance when administered to
rats previously treated with an initiator suoh as
DENA, to enhance the incidence of GGTase-positive
foci and/or decrease the latent period for the ap-
pearance of foci has been purposed as a short-term
screen for hepatic tumor promoters. The test sub-
stance in animals not initiated should have no effect
on the incidence of foci. Substances that have been
tested for their ability to enhance the incidence of
carcinogen-initiated GGTase-positive foci and/or to
promote tumor formation are presented in Table 3.
Compound
Amobarbital
Barbital
5,7-Dibromo-8-hydroquinolone
Dichlorodiphenyltrichloro-
ethane (DDT)
Diphenylhydantoin
DL-Ethionine
Hexachlorobenzene
Hexobarbital
8-Hydroxyquinoline
Lindane
Mestranol
8-Nitroquinoline
Norethynodrel
Pentabarbital
Phenobarbital
Polychlorinated biphenyls
Quinoline
2,3,7,8-Tetrachlorodibenzo-
p-dioxin (TCDD)
Table 3. Evaluation of chemicals as promoters of rat liver tumors.
Route Endpoint Result
Diet Tumors Negative
Water Foci Negative
Water Foci Positive
Diet Tumors Negative
Systemic Tumors Negative
Diet Tumors Positive
Diet Tumors Negative
Diet Tumors Positive
Diet Foci Positive
Water Foci Negative
Diet Tumors Negative
Diet Foci Positive
Diet Foci Positive
Diet Tumors Negative
Diet Foci Negative
Water Foci Negative
Diet Foci/tumors Positive
Water Foci/tumors Positive
Diet Foci/tumors Positive
Systemic Foci/tumors Positive
Diet Tumors Positive
Systemic Foci Positive
References
(33)
(34)
(34)
(35)
(36)
(33)
(33)
(37)
(35)
(34)
(37)
(35)
(36)
(37)
(36)
(34)
(24,26-28,33,36)
(10,29,34,38)
(29,38,39)
(30)
(37)
(40)
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Enhancers of the growth and incidence of GGTase-
positive foci and/or tumor promoters in rat liver
include drugs, hormones and environmental contam-
inants. A confounding effect in the evaluation of
some of the enhancers of GGTase-positive foci was
their induction in zone one (as defined by Rappa-
port) of GGTase activity (41). This zonal induction
was observed in hexachlorbenzene-, lindane-, mes-
tranol- and phenobarbital-treated rats and was of
such a magnitude as to prevent the reading of some
of the slides for the occurrence of foci. Where
determined, there was a correlation between the
ability of a substance to enhance foci formation and
to promote tumor formation. This correlation was
expected in view of the proposed precursor nature
of the foci to hepatoceilular carcinoma. In the
presence of a promoter, maximum incidence of foci
developed by 3 months which was much earlier than
the appearance oftumors. Therefore, the ability of a
substance to enhance the formation of GGTase- pos-
itive foci can be used as a short-term screen for
liver tumor promoters. However, the confirmation
that the substance which enhanced foci formation is
a tumor promoter requires the actual demon-
stration of a decreased latent period for tumor
promotion.
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